ArticleCancer discovery2017
Modeling Renal Cell Carcinoma in Mice:
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 1 pooled it
11.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 1 synthesis or guideline pooled it, 170 citations in OpenAlex.
- New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Guideline
- A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.Cancer discovery · 2022Trial
- Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma.European urology · 2022Trial
- A tailored in vivo CRISPR screen identifies BAP1 as a potent tumor suppressor of sarcoma.JCI insight · 2026Article
- BAP1 deficiency-induced SKA3 promotes clear cell renal cell carcinoma malignant progression by regulating chromosomal instability.Cell death & disease · 2026Article
- Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas: current understanding and perspectives on malignant progression.Journal of gastroenterology · 2026Review
- Emerging roles for the epigenetic modifiers PBRM1 SETD2 and BAP1 in clear cell renal cell carcinoma pathogenesis and prognosis beyond VHL.Discover oncology · 2026Review
- Disulfidptosis induced by intermittent fasting and metformin enhances the efficacy of anti-PD-1 therapy in renal cancer.Cell communication and signaling : CCS · 2026Article
- Determinants of pancreatic tropism in metastatic renal cell carcinoma.JCI insight · 2026Article
- PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1-KDM5C-IL6 Axis in ccRCC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Distinct genomic, microenvironmental, and nephron signatures in VHL kidney cysts and tumors.Scientific reports · 2026Article
- VHL Gene Restoration Supports RCC Reprogramming to iPSCs but Does Not Ensure Line Stability.Cancers · 2025Article
- Determinants of late metastases in renal cell carcinoma.Journal of the National Cancer Institute · 2025Article
- Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance.Scientific reports · 2025Article
- Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial.Nature communications · 2025Article
- Clear cell renal carcinoma essentially requires CDKL3 for oncogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- BBOX1 restrains TBK1-mTORC1 oncogenic signaling in clear cell renal cell carcinoma.Nature communications · 2025Article
- BAP1 complexes with YY1 and RBBP7 and its downstream targets in ccRCC cells.Open life sciences · 2025Article
- Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC).International journal of molecular sciences · 2024Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 4 institutions in 2 countries.
Yi-Feng GuDepartment of Internal Medicine, Hematology-Oncology Division, The University of Texas Southwestern Medical Center, Dallas, Texas.
Shannon CohnDepartment of Internal Medicine, Hematology-Oncology Division, The University of Texas Southwestern Medical Center, Dallas, Texas.
Alana ChristieKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Tiffani McKenzieKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Nicholas WolffDepartment of Internal Medicine, Hematology-Oncology Division, The University of Texas Southwestern Medical Center, Dallas, Texas.
Quyen N DoDepartment of Radiology and the Advanced Imaging Research Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Ananth J MadhuranthakamDepartment of Radiology and the Advanced Imaging Research Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Ivan PedrosaKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Tao WangKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Anwesha DeyDepartment of Molecular Oncology, Genentech, South San Francisco, California.
Meinrad BusslingerThe Research Institute of Molecular Pathology, Vienna, Austria.
Xian-Jin XieKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Robert E HammerDepartment of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, Texas.
Renée M McKayDepartment of Internal Medicine, Hematology-Oncology Division, The University of Texas Southwestern Medical Center, Dallas, Texas.
Payal KapurKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas. james.brugarolas@utsouthwestern.edu payal.kapur@utsouthwestern.edu.
James BrugarolasDepartment of Internal Medicine, Hematology-Oncology Division, The University of Texas Southwestern Medical Center, Dallas, Texas. james.brugarolas@utsouthwestern.edu payal.kapur@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USAdvanced Imaging Research (United States) · USMolecular Oncology (United States) · USResearch Institute of Molecular Pathology · AT
Funding
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7MUniversity of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI James Brugarolas · 2016 to 2026
$24.7MNON-INVASIVE PHYSIOLOGIC PREDICTORS OF AGGRESSIVENESS IN RENAL CELL CARCINOMAR01CA154475 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI PEDROSA, IVAN · 2011 to 2024
$4.3MEvaluation of the BAP1 tumor suppressor gene in renal cell carcinomaR01CA175754 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI BRUGAROLAS, JAMES · 2014 to 2018
$1.6MDevelopment of integrative models for early liver toxicity assessmentR03ES026397 · NIEHS · UT SOUTHWESTERN MEDICAL CENTER · PI WANG, TAO · 2016 to 2017
$162kNCI NIH HHS P30 CA142543NCI NIH HHS P50 CA196516NCI NIH HHS R01 CA154475NCI NIH HHS R01 CA175754NIEHS NIH HHS R03 ES026397
Abstract
Clear cell renal cell carcinoma (ccRCC) is characterized by
Indexed as
AnimalsCarcinogenesisCarcinoma, Renal CellDisease Models, AnimalDNA-Binding ProteinsGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHMGB ProteinsHumansMiceMicrofilament ProteinsMutationPrognosisSodium-Glucose Transporter 2Transcription FactorsTumor Suppressor ProteinsBAP1 protein, mouseDNA-Binding ProteinsHMGB ProteinsMicrofilament ProteinsPbrm1 protein, mouseSlc5a2 protein, mouseSodium-Glucose Transporter 2Transcription FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseVHL protein, mousevillinVon Hippel-Lindau Tumor Suppressor Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.